ICER panel split on value of CAR Ts

The Institute for Clinical and Economic Review's California Technology Assessment Forum voted that the value of Kymriah tisagenlecleucel was intermediate, while the panel

Read the full 232 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE